Article Information
PMID
Published By
Print ISSN
0250-7005
Online ISSN
1791-7530
History
- Received May 23, 2020
- Revision received June 19, 2020
- Accepted June 23, 2020
- Published online July 29, 2020.
Copyright & Usage
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
Author Information
- KAZUSHI YAMAMOTO1⇑,
- HARUKA MIZOBUCHI1,
- MASASHI YAMASHITA1,
- HIROYUKI INAGAWA1,2,3,
- CHIE KOHCHI2 and
- GEN-ICHIRO SOMA1,2,3
- 1Department of Control of Innate Immunity, Technology Research Association, Kagawa, Japan
- 2Macrophi Inc., Kagawa, Japan
- 3Research Institute for Healthy Living, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan
- Correspondence to: Dr. Kazushi Yamamoto, Control of Innate Immunity, Technology Research Association, 2217-16 Hayashi-cho, Takamatsu-shi, Kagawa 761-0301, Japan. Tel: +81 878139201, Fax: +81 878139203, e-mail: yamamoto{at}shizenmeneki.org
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Combination of 3-(Trihydroxygermyl)propanoic Acid (THGP) and Lipopolysaccharide Promotes Macrophage Differentiation to M1, and Antitumor Activity
- Suppression of Inflammatory Cytokine Genes Expression in Vascular Endothelial Cells by Super-low Dose Lipopolysaccharide-activated Macrophages
- Anti-inflammatory and Insulin Signaling Phenotype Induced by Repeated Lipopolysaccharide Stimulation in 3T3-L1 Adipocytes